AstraZeneca faces new patent fight over Nexium

India's Ranbaxy has launched a bid to manufacture a copycat version of AstraZeneca's blockbuster Nexium. The Anglo-Swedish drug giant immediately issued its own challenge, saying that it controlled Nexium's patent until 2018 and that any court fight over the patent would likely take years to play out. Teva Pharmaceuticals recently made a bid to go after another AstraZeneca drug, Seroquel.

- read this article from Times Online for more

Suggested Articles

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes.